Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Operating Expenses (2017 - 2025)

Aclaris Therapeutics has reported Other Operating Expenses over the past 9 years, most recently at $1.9 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $1.9 million for Q4 2025, down 98.03% from a year ago — trailing twelve months through Dec 2025 was $9.6 million (down 90.86% YoY), and the annual figure for FY2025 was $9.6 million, down 90.86%.
  • Other Operating Expenses for Q4 2025 was $1.9 million at Aclaris Therapeutics, down from $2.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for ACRS hit a ceiling of $94.9 million in Q4 2024 and a floor of -$13.2 million in Q4 2023.
  • Median Other Operating Expenses over the past 5 years was $2.9 million (2024), compared with a mean of $7.9 million.
  • Peak annual rise in Other Operating Expenses hit 2475.56% in 2023, while the deepest fall reached 253.74% in 2023.
  • Aclaris Therapeutics' Other Operating Expenses stood at $3.3 million in 2021, then skyrocketed by 157.21% to $8.6 million in 2022, then plummeted by 253.74% to -$13.2 million in 2023, then skyrocketed by 816.65% to $94.9 million in 2024, then crashed by 98.03% to $1.9 million in 2025.
  • The last three reported values for Other Operating Expenses were $1.9 million (Q4 2025), $2.5 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.